This site is intended for health professionals only
Hospital Healthcare Europe
Register
Login
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
In depth
Views
Conference reports
Reviews & Research
Practice
Health technology
Sustainability
Clinical
Cardiovascular
Dermatology
Emergency and critical care
Gastroenterology
Haematology
Immunology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Events
Upcoming events
On-demand learning
Clinical Excellence Catch-up
Partners
Register
Login
News
In depth
Views
Conference reports
Reviews & Research
Practice
Health technology
Sustainability
Clinical
Cardiovascular
Dermatology
Emergency and critical care
Gastroenterology
Haematology
Immunology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Events
Upcoming events
On-demand learning
Clinical Excellence Catch-up
Partners
Register
Login
Home
>
Opinion/comment
Opinion/comment
What next for dupilumab?
The EBMT Pharmacist Committee
Drug stability in the clinical environment
Sun safety
Heralding a new era in specialty pharmacy practice
Vitamin D for musculoskeletal health: is it a load of old bones?
CHMP positive opinion for opioid dependence treatment with buprenorphine/naloxone
Lundbeck receives positive opinion for approval of Selincro in EU
Expert opinion: hereditary angioedema
NICE reverses negative opinion on osteosarcoma drug
Nosocomial pneumonia treatment receives positive opinion
PROFILE: Thomas Lonngren
1
2
3
…
8
Next »
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: